1. Home
  2. PBMWW vs HBB Comparison

PBMWW vs HBB Comparison

Compare PBMWW & HBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBMWW
  • HBB
  • Stock Information
  • Founded
  • PBMWW N/A
  • HBB 1904
  • Country
  • PBMWW Canada
  • HBB United States
  • Employees
  • PBMWW 10
  • HBB N/A
  • Industry
  • PBMWW
  • HBB Home Furnishings
  • Sector
  • PBMWW
  • HBB Consumer Discretionary
  • Exchange
  • PBMWW Nasdaq
  • HBB Nasdaq
  • Market Cap
  • PBMWW N/A
  • HBB N/A
  • IPO Year
  • PBMWW N/A
  • HBB 2017
  • Fundamental
  • Price
  • PBMWW $0.01
  • HBB $30.40
  • Analyst Decision
  • PBMWW
  • HBB
  • Analyst Count
  • PBMWW 0
  • HBB 0
  • Target Price
  • PBMWW N/A
  • HBB N/A
  • AVG Volume (30 Days)
  • PBMWW N/A
  • HBB 65.6K
  • Earning Date
  • PBMWW N/A
  • HBB 10-30-2024
  • Dividend Yield
  • PBMWW N/A
  • HBB 1.51%
  • EPS Growth
  • PBMWW N/A
  • HBB 313.35
  • EPS
  • PBMWW N/A
  • HBB 2.47
  • Revenue
  • PBMWW N/A
  • HBB $644,781,000.00
  • Revenue This Year
  • PBMWW N/A
  • HBB $4.60
  • Revenue Next Year
  • PBMWW N/A
  • HBB N/A
  • P/E Ratio
  • PBMWW N/A
  • HBB $11.78
  • Revenue Growth
  • PBMWW N/A
  • HBB 5.28
  • 52 Week Low
  • PBMWW N/A
  • HBB $10.88
  • 52 Week High
  • PBMWW N/A
  • HBB $31.05
  • Technical
  • Relative Strength Index (RSI)
  • PBMWW N/A
  • HBB 59.12
  • Support Level
  • PBMWW N/A
  • HBB $29.27
  • Resistance Level
  • PBMWW N/A
  • HBB $31.02
  • Average True Range (ATR)
  • PBMWW 0.00
  • HBB 1.21
  • MACD
  • PBMWW 0.00
  • HBB -0.13
  • Stochastic Oscillator
  • PBMWW 0.00
  • HBB 77.51

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: